Pauline Girard, Pascal Auquier, Vincent Barlogis, Audrey Contet, Maryline Poiree, François Demeocq, Julie Berbis, Iris Herrmann, Virginie Villes, Nicolas Sirvent, Justyna Kanold, Pascal Chastagner, Hervé Chambost, Dominique Plantaz and Gérard Michel

Haematologica. 2013 Jul;98(7):1089-97.

https://pubmed.ncbi.nlm.nih.gov/23645686/

Corticosteroid can induce osteonecrosis in children with leukemia. Few studies have been designed to assess the influence of a wide range of cumulative steroid dose on this side effect. Prevalence, risk factors of symptomatic osteonecrosis and its impact on adults’ Quality of Life were assessed in 943 patients enrolled in the French « Leucémies de l’Enfant et de l’Adolescent » (LEA) cohort of childhood leukemia survivors. During each medical visit, data on previous osteonecrosis diagnosis were retrospectively collected. Patients without a history but with suggestive symptoms were investigated with magnetic resonance imaging.

The total steroid dose in equivalent of prednisone was calculated for each patient and its effect on osteonecrosis occurrence was studied in multivariate models. Cumulative incidence was 1.4% after chemotherapy alone versus 6.8% after transplantation (P<0.001). A higher cumulative steroid dose, age over ten years at diagnosis, and treatment with transplantation significantly increased the risk of osteonecrosis. A higher post-transplant steroid dose and age over ten years at time of transplantation were significant factors in the transplanted group.

With patients grouped according to steroid dose quartile, cumulative incidence of osteonecrosis reached 3.8% in the chemotherapy group for a dose beyond 5835 mg/m(2) and 23.8% after transplantation for a post-transplant dose higher than 2055 mg/m(2). Mean physical composite score of Quality of Life was 44.3 in patients with osteonecrosis versus 54.8% in patients without (P<0.001).

We conclude that total and post-transplant cumulative steroid dose may predict the risk of osteonecrosis, a rare late effect with a strong negative impact on physical domains of Quality of Life.

Pauline Girard, Pascal Auquier, Vincent Barlogis, Audrey Contet, Maryline Poiree, François Demeocq, Julie Berbis, Iris Herrmann, Virginie Villes, Nicolas Sirvent, Justyna Kanold, Pascal Chastagner, Hervé Chambost, Dominique Plantaz and Gérard Michel

Haematologica. 2013 Jul;98(7):1089-97.

Consulter d’autres publications

40. Impact of childhood leukemia on siblings: their long-term perception of family functioning and its relationship with their psychosocial characteristics using structural equation modeling

39. Misconceptions and beliefs around hormone replacement therapy after childhood hematopoietic stem cell transplantation: A qualitative study among women leukemia survivors

38. Ovarian Function and Spontaneous Pregnancy After Hematopoietic Stem Cell Transplantation for Leukemia Before Puberty: An L.E.A. Cohort Study

37. Symptomatic osteonecrosis in French survivors of childhood and adolescent leukemia: a clinical and MRI study of LEA cohort

36. The uterine volume is dramatically decreased after hematopoietic stem cell transplantation during childhood regardless of the conditioning regimen

35. Brothers and sisters of childhood acute leukemia survivors: Their long-term quality of life and its determinants

34. Bone mineral density evolution and its determinants in long-term survivors of childhood acute leukemia: a L.E.A. study

33. Testosterone deficiency in men surviving childhood acute leukemia after treatment with hematopoietic stem cell transplantation or testicular radiation: an L.E.A. study

32. Quality of life in parents of childhood leukemia survivors. A French Childhood Cancer Survivor Study for Leukemia study.

31. Lipodystrophy-like features after total body irradiation among survivors of childhood acute leukemia.

30. Prevalence and characteristics of metabolic syndrome in adults from the French childhood leukemia survivors’ cohort: a comparison with controls from the French population.

29. Adolescence and Socioeconomic Factors: Key Factors in the Long-Term Impact of Leukemia on Scholastic Performance—A LEA Study.

28. Metabolic Syndrome Among Leukemia Survivors: Still Delineating the Risk.

27. A French national breast and thyroid cancer screening programme for survivors of childhood, adolescent and young adult (CAYA) cancers – DeNaCaPST programme.

26. Late effects in survivors of infantile acute leukemia: a study of the L.E.A program.

25. Metabolic syndrome in long-term survivors of childhood acute leukemia treated without hematopoietic stem cell transplantation: an L.E.A. study.

24. Employment in French young adult survivors of childhoodleukemia: an LEA study (for Leucemies de l’Enfant et de l’Adolescent—childhood and adolescent leukemia)

23. The Impact of Donor Type on Long-Term Health Status and Quality of Life after Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Leukemia: A Leucémie de l’Enfant et de L’Adolescent Study.

22. Late thyroid complications in survivors of childhood acute leukemia. An L.E.A. study.

21. Educational and occupational outcomes of childhood cancer survivors 30 years afterdiagnosis: a French cohort study.

20. Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study.

19. Metabolic syndrome in adults who received hematopoietic stem cell transplantation for acute childhood leukemia: an LEA study.

18. Quality of life in minor siblings of childhood leukemia survivors, long-term after diagnosis: A LEA study (for Leucemies de l’Enfant et de l’Adolescent – childhood and adolescent leukemia).

17. Late cardiomyopathy in childhood acute myeloid leukemia survivors: an L.E.A. study.

16. Childhood cancer survivor cohorts in Europe.

15. Health status and quality of life of long-term survivors of childhood acute leukemia: the impact of central nervous system irradiation.

14. Cohort Profile: The French Childhood Cancer Survivor Study For Leukaemia (LEA Cohort).

13. Incidence and risk factors for cataract after haematopoietic stem cell transplantation for childhood leukaemia: an LEA study.

12. Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study.

11. Prevalence and risk factors of cataract after chemotherapy with or without central nervous system irradiation for childhood acute lymphoblastic leukaemia: an LEA study.

9. A French Cohort of Childhood Leukemia Survivors: Impact of Hematopoietic Stem Cell Transplantation on Health Status and Quality of Life.

8. Adherence to Leukemia Maintenance Therapy: A Comparative Study Among Children, Adolescents, and Adults.

7. The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): Development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer.

6. Growth hormone treatment impact on growth rate and final height of patients who received HSCT with TBI or/and cranial irradiation in childhood: a report from the French Leukaemia Long-Term Follow-UpStudy (LEA).

5. Bone mineral density in adult-survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities.

4. Quality of life in a heterogeneous sample of caregivers of cancer patients: an in-depth interview study.

3. Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia.

2. Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI.

1. Health status and quality of life in long-term survivors of childhood leukaemia: the impact of haematopoietic stem cell transplantation.